Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Molnupiravir  COVID-19 treatment studies for Molnupiravir  C19 studies: Molnupiravir  Molnupiravir   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent: 
0 0.5 1 1.5 2+ ICU admission -162% Improvement Relative Risk Progression 8% Hospitalization time 18% Time to viral- 21% Viral clearance, day 21 -23% Viral clearance, day 14 28% Viral clearance, day 10 38% Viral clearance, day 7 18% Viral clearance, day 5 12% c19early.org/m Liu et al. Molnupiravir for COVID-19 EARLY TREATMENT Favors molnupiravir Favors control
Disease Progression of Hospitalized Elderly Patients with Omicron BA.2 Treated with Molnupiravir
Liu et al., Infectious Diseases and Therapy, doi:10.1007/s40121-022-00716-7
30 Oct 2022    Source   PDF   Share   Tweet
Retrospective 42 elderly patients in China showing faster viral clearance with molnupiravir.
Concerns have been raised that the mutagenic mechanism of action may create dangerous variants or cause cancer [Hadj Hassine, Swanstrom].
risk of ICU admission, 161.5% higher, RR 2.62, p = 1.00, treatment 1 of 26 (3.8%), control 0 of 16 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of progression, 7.7% lower, RR 0.92, p = 1.00, treatment 3 of 26 (11.5%), control 2 of 16 (12.5%), NNT 104, dyspnea or ICU.
hospitalization time, 17.9% lower, relative time 0.82, p = 0.14, treatment 26, control 16.
time to viral-, 21.4% lower, relative time 0.79, p = 0.10, treatment 26, control 16.
risk of no viral clearance, 23.1% higher, RR 1.23, p = 1.00, treatment 2 of 26 (7.7%), control 1 of 16 (6.2%), day 21.
risk of no viral clearance, 28.2% lower, RR 0.72, p = 0.51, treatment 7 of 26 (26.9%), control 6 of 16 (37.5%), NNT 9.5, day 14.
risk of no viral clearance, 38.5% lower, RR 0.62, p = 0.04, treatment 14 of 26 (53.8%), control 14 of 16 (87.5%), NNT 3.0, day 10.
risk of no viral clearance, 17.9% lower, RR 0.82, p = 0.22, treatment 20 of 26 (76.9%), control 15 of 16 (93.8%), NNT 5.9, day 7.
risk of no viral clearance, 11.5% lower, RR 0.88, p = 0.28, treatment 23 of 26 (88.5%), control 16 of 16 (100.0%), NNT 8.7, day 5.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Liu et al., 30 Oct 2022, retrospective, China, peer-reviewed, median age 84.0, 10 authors, study period 26 March, 2022 - 31 May, 2022.
Contact: liangxuesong2000@163.com, 452055289@qq.com, redmaples2005@163.com, 18351977696@163.com, zhongwu@bmi.ac.cn, xuaijing86@163.com, fansy@bmi.ac.cn, 1042956281@qq.com, 617943178@qq.com, yxdongxu@126.com.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperMolnupiravirAll
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit